Quick Takeaways
- GILEAD SCIENCES, INC. filed SCHEDULE 13D/A for Arcus Biosciences, Inc. Common Stock, par value $0.0001 (RCUS).
- Disclosed ownership: 26%.
- Date of event: 03 Nov 2025.
GILEAD SCIENCES, INC. - 03 Nov 2025 SCHEDULE 13D/A Report for Arcus Biosciences, Inc. Common Stock, par value $0.0001 (RCUS)
- Filing Manager
- GILEAD SCIENCES, INC.
- Reporting Manager
- GILEAD SCIENCES, INC.
- Symbol
- RCUS
- Shares outstanding
- 122,752,969 shares
- Disclosed Ownership
- 31,424,760 shares
- Ownership
- 26%
- Form type
- SCHEDULE 13D/A
- Filing time
- 05 Nov 2025, 17:19:42 UTC
- Date of event
- 03 Nov 2025
- Previous filing
- 15 Jul 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GILEAD SCIENCES, INC. disclosed 26% ownership in Arcus Biosciences, Inc. Common Stock, par value $0.0001 (RCUS) on 03 Nov 2025."
What Changed
- Previous schedule filing date: 15 Jul 2025.
- Current filing was accepted on 05 Nov 2025, 17:19.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 26% | 31,424,760 | 31,424,760 | 0 | /s/ Andrew D. Dickinson | Andrew D. Dickinson, Executive Vice President and Chief Financial Officer | 0000882095 |